Oxaliplatin News and Research

RSS

Researchers study new drug and indications for heated chemotherapy treatment

Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer.

17 Mar 2008

Barr Pharmaceuticals confirms Eloxatin injectable patent challenge

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Sanofi-Aventis U.S. LLC in connection with its Eloxatin(R) (Oxaliplatin Aqueous Solution), 5mg/mL Injectable.

10 Jan 2008

Phase II study of TroVax vaccine in patients with metastatic colorectal cancer

A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd.

2 Aug 2007

Study of therapeutic vaccine shows promise for metastatic colorectal cancer

1 Aug 2007

Sequential and combination chemotherapy equally effective in treating advanced colorectal cancer

Many patients with incurable advanced colorectal cancer could be offered a more gentle treatment strategy starting with a single chemotherapy drug, as an alternative to current standard initial combination chemotherapy, without compromising their survival.

16 Jul 2007

Physiological differences between men and women impact colorectal cancer progression

Physiological differences between men and women may contribute to differential tumor development and progression in colon cancer patients, a study led by researchers at the University of Southern California (USC) suggests.

5 Jun 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.

3 May 2006

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer

A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI) - the administration of chemotherapy directly to the liver through a pump in the abdomen - fare better than those who received traditional, intravenous chemotherapy.

1 Mar 2006

Mangafodipir appears to increase the cancer-killing ability of some chemotherapy drugs

A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.

21 Feb 2006

FOLFOX now treatment standard for colorectal cancer in the United States

One of the newest and most potent chemotherapies for colon cancer is as safe and effective for the elderly as it is for younger patients, based on a University of North Carolina at Chapel Hill-led data review.

16 Feb 2006

Chemotherapy options improve for patients with advanced colorectal cancer

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC).

6 Jun 2005

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

"Even in people who have gone through six or more previous courses of chemotherapy, cetuximab, may fight the growth of cancer, giving patients additional months of life," says study presenter Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center.

20 May 2005

Genetic biomarker that may improve quality of life during treatment for colorectal cancer

A Mayo Clinic-led study has revealed a genetic biomarker that can predict which patients are most likely to experience unwanted side effects from one of the most commonly used and highly effective chemotherapy regimens designed to treat colorectal cancer.

16 May 2005

New cancer drug Avastin keeps cancer under control

Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps cancer under control for a significantly longer duration, even when used in a group of elderly patients with advanced colorectal cancer who are too sick to tolerate traditional aggressive chemotherapy.

1 Mar 2005

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Erbitux (cetuximab), offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an article written by two Mayo Clinic cancer researchers published in the current edition of the New England Journal of Medicine.

21 Jul 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

Northern Ireland scientists target bowel cancer treatment

Cancer Research N. Ireland scientists are developing a way for doctors to predict which treatment will be most successful in individual bowel cancer patients.

28 Apr 2004

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004